DUBLIN--(BUSINESS WIRE)--The "Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
Drug discovery services market to register a CAGR of 12.1% from 2020 to 2025.
The growth of the industry is driven primarily by factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. Growth in the biologics market and patent expiries will further provide opportunities in the drug discovery services industry. Developing economies are expected to offer a wide range of growth opportunities for players in the market.
The Hit-to-Lead process segment is anticipated to grow at the fastest growth rate during the forecast period.
Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.
Medicinal Chemistry segment is estimated to account for the largest share of the drug discovery services market in 2020.
Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.
Oncology segment is anticipated to grow at the fastest growth rate during the forecast period.
Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market in 2019. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.
North America is expected to dominate the drug discovery services market in 2020.
North America, which includes the US and Canada, is estimated to account for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.
Reasons to Buy the Report:
- Market Penetration: Comprehensive information on the drug discovery services offered by the key 20 players in the drug discovery services market. The report analyzes the drug discovery services market by process, type, drug type, therapeutic area, company type, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various drug discovery services, their adoption, type of applications across key geographic regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the drug discovery services market along with a competitive leadership mapping of up to 25 players in the market.
Key Topics Covered:
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Research Data
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Drug Discovery Services Market Overview
4.2 North America: Market, By Drug Type & Country (2020)
4.3 Market: Geographic Growth Opportunities
5 Market Overview
5.2 Market Dynamics
6 Drug Discovery Services Market, By Process
6.2 Target Selection
6.3 Target Validation
6.4 Hit-To-Lead Identification
6.5 Lead Optimization
6.6 Candidate Validation
7 Drug Discovery Services Market, By Type
7.2 Medicinal Chemistry Services
7.3 Biology Services
7.4 Drug Metabolism & Pharmacokinetics
8 Drug Discovery Services Market, By Drug Type
8.2 Small-Molecule Drugs
8.3 Biologic Drugs
9 Drug Discovery Services Market, By Therapeutic Area
9.4 Infectious and Immune System Diseases
9.5 Digestive System Diseases
9.6 Cardiovascular Diseases
9.7 Other Therapeutic Areas
10 Drug Discovery Services Market, By Company Type
10.2 Tier 1 Pharmaceutical Companies
10.3 Tier 2 Pharmaceutical Companies
10.4 Tier 3 Pharmaceutical Companies
11 Drug Discovery Services Market, By Region
11.2 North America
11.4 Asia Pacific
11.5 Rest of the World
12 Competitive Landscape
12.2 Market Share Analysis
12.3 Competitive Scenario
12.4 Competitive Leadership Mapping
13 Company Profiles
13.1 Laboratory Corporation of America Holdings
13.2 Eurofins Scientific Se
13.3 Charles River Laboratories International
13.4 Evotec SE
13.5 Thermo Fisher Scientific
13.6 Albany Molecular Research, Inc.
13.7 Syngene International Limited
13.8 Jubilant Lifesciences
13.9 Genscript Biotech Corporation
13.10 Piramal Enterprises Limited
13.11 Selvita S.A.
13.12 Aurigene Discovery Technologies
13.13 Domainex Ltd.
13.14 WuXi AppTec
13.15 Chempartner Co., Ltd.
13.16 Frontage Holdings
13.17 Pharmaceutical Product Development, LLC
13.18 Shanghai Medicilon, Inc.
13.19 TCG Lifesciences Pvt. Limited
13.20 Viva Biotech (Shanghai) Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/i0k3fl